Interferon Beta 1a in COVID-19: A Randomized, Double-Blind, Placebo-Controlled, Clinical Trial
Condition: COVID-19 Interventions: Drug: Interferon Beta-1A; Drug: Lopinavir / Ritonavir; Drug: Single Dose of Hydroxychloroquine Sponsor: Shahid Beheshti University of Medical Sciences Enrolling by invitation (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 17, 2020 Category: Research Source Type: clinical trials
An Investigation Into Beneficial Effects of Interferon Beta 1a, Compared to Interferon Beta 1b And The Base Therapeutic Regiment in Moderate to Severe COVID-19: A Randomized Clinical Trial
Condition: COVID-19 Interventions: Drug: Hydroxychloroquine; Drug: Lopinavir / Ritonavir; Drug: Interferon Beta-1A; Drug: Interferon Beta-1B Sponsor: Shahid Beheshti University of Medical Sciences Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 13, 2020 Category: Research Source Type: clinical trials
An Investigation Into Beneficial Effects of Interferon Beta 1a, Compared to Interferon Beta 1b And The Base Therapeutic Regiment in Moderate to Severe COVID-19: A Randomized Clinical Trial
Condition: COVID-19 Interventions: Drug: Hydroxychloroquine; Drug: Lopinavir / Ritonavir; Drug: Interferon Beta-1A; Drug: Interferon Beta-1B Sponsor: Shahid Beheshti University of Medical Sciences Enrolling by invitation (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 13, 2020 Category: Research Source Type: clinical trials
An Investigation Into Beneficial Effects of Interferon Beta 1a, Compared to Interferon Beta 1b And The Base Therapeutic Regiment in Moderate to Severe COVID-19: A Randomized Clinical Trial
Condition: COVID-19 Interventions: Drug: Hydroxychloroquine; Drug: Lopinavir / Ritonavir; Drug: Interferon Beta-1A; Drug: Interferon Beta-1B Sponsor: Shahid Beheshti University of Medical Sciences Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 13, 2020 Category: Research Source Type: clinical trials
An Investigation Into Beneficial Effects of Interferon Beta 1a, Compared to Interferon Beta 1b And The Base Therapeutic Regiment in Moderate to Severe COVID-19: A Randomized Clinical Trial
Condition: COVID-19 Interventions: Drug: Hydroxychloroquine; Drug: Lopinavir / Ritonavir; Drug: Interferon Beta-1A; Drug: Interferon Beta-1B Sponsor: Shahid Beheshti University of Medical Sciences Enrolling by invitation (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 13, 2020 Category: Research Source Type: clinical trials
An Investigation Into Beneficial Effects of Interferon Beta 1a, Compared to Interferon Beta 1b And The Base Therapeutic Regiment in Moderate to Severe COVID-19: A Randomized Clinical Trial
Condition: COVID-19 Interventions: Drug: Hydroxychloroquine; Drug: Lopinavir / Ritonavir; Drug: Interferon Beta-1A; Drug: Interferon Beta-1B Sponsor: Shahid Beheshti University of Medical Sciences Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 13, 2020 Category: Research Source Type: clinical trials
Pharmacodynamic Biomarkers to Support Biosimilar Development: Interferon Beta-1A Products
Conditions: Healthy Subjects; Pharmacokinetics; Pharmacodynamics Interventions: Biological: Interferon beta-1a; Biological: Peginterferon beta-1a; Biological: Placebo Sponsors: Food and Drug Administration (FDA); Spaulding Clinical Research LLC Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 3, 2019 Category: Research Source Type: clinical trials
